Page last updated: 2024-08-26

nicotine and risperidone

nicotine has been researched along with risperidone in 28 studies

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's17 (60.71)29.6817
2010's11 (39.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA1
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY2
Keserü, GM1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Jia, L; Sun, H1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM1
Ahman, M; Holmén, AG; Wan, H1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Giordanetto, F; Leach, AG; Zachariae, U1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Bellman, K; Knegtel, RM; Settimo, L1
Addy, N; Levin, ED1
Levin, ED; Rezvani, AH1
Andersen, KK; Andreasen, JT; Mathiasen, L; Mirza, NR; Nielsen, EØ1
Caldwell, DP; Levin, ED; Rezvani, AH1
Harvey, I; Lilford, R; Song, F1
Akdag, E; Kayir, H; Uzbay, TI1
Craig, KJ; Dadhiwala, R; Dawson, GR; Deakin, JF; Dourish, CT; Ettinger, U; Grayson, L; Koychev, I; Lees, J; McMullen, K; Migo, EM; Morris, R; Perry, C; Schmechtig, A; Wilkinson, L; Williams, SC1
Dawson, GR; Dourish, CT1
Grayson, B; Harte, MK; Marsh, S; McLean, SL; Neill, JC; Zarroug, SH1
Banks, ML; Blough, BE; Smith, DA1

Reviews

1 review(s) available for nicotine and risperidone

ArticleYear
Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions.
    Journal of clinical epidemiology, 2008, Volume: 61, Issue:5

    Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bias; Bupropion; Data Interpretation, Statistical; Drug Therapy; Fluoxetine; Haloperidol; Humans; Imipramine; Meta-Analysis as Topic; Nicotine; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Smoking Cessation; Treatment Outcome

2008

Trials

1 trial(s) available for nicotine and risperidone

ArticleYear
Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy.
    Psychopharmacology, 2013, Volume: 227, Issue:2

    Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Nicotine; Psychometrics; Pursuit, Smooth; Risperidone; Saccades; Schizotypal Personality Disorder; Sulpiride; Surveys and Questionnaires; Young Adult

2013

Other Studies

26 other study(ies) available for nicotine and risperidone

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
    Journal of medicinal chemistry, 2001, Jul-19, Volume: 44, Issue:15

    Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water

2001
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
    Journal of medicinal chemistry, 2002, Jun-20, Volume: 45, Issue:13

    Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding

2002
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
    Bioorganic & medicinal chemistry letters, 2003, Aug-18, Volume: 13, Issue:16

    Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship

2003
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
    Journal of medicinal chemistry, 2004, Feb-26, Volume: 47, Issue:5

    Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution

2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Support vector machines classification of hERG liabilities based on atom types.
    Bioorganic & medicinal chemistry, 2008, Jun-01, Volume: 16, Issue:11

    Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve

2008
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
    Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19

    Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship

2008
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
    Journal of medicinal chemistry, 2009, Mar-26, Volume: 52, Issue:6

    Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry

2009
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
    Journal of medicinal chemistry, 2009, Jul-23, Volume: 52, Issue:14

    Topics: Binding Sites; Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Ligands; Models, Molecular; Potassium Channel Blockers; Protein Binding; Protein Conformation

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
    Pharmaceutical research, 2014, Volume: 31, Issue:4

    Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation

2014
Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2002, Volume: 27, Issue:4

    Topics: Animals; Antipsychotic Agents; Brain; Clozapine; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Female; Haloperidol; Maze Learning; Memory, Short-Term; Neural Pathways; Nicotine; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Dopamine; Risperidone; Schizophrenia

2002
Nicotine-antipsychotic drug interactions and attentional performance in female rats.
    European journal of pharmacology, 2004, Feb-20, Volume: 486, Issue:2

    Topics: Animals; Antipsychotic Agents; Attention; Central Nervous System Stimulants; Clozapine; Dose-Response Relationship, Drug; Drug Interactions; Female; Haloperidol; Nicotine; Photic Stimulation; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Risperidone

2004
Nicotine and clozapine selectively reverse a PCP-induced deficit of PPI in BALB/cByJ but not NMRI mice: comparison with risperidone.
    Behavioural brain research, 2006, Feb-15, Volume: 167, Issue:1

    Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Dose-Response Relationship, Drug; Drug Interactions; Female; Hallucinogens; Mice; Mice, Inbred BALB C; Neural Inhibition; Nicotine; Nicotinic Agonists; Phencyclidine; Reflex, Startle; Risperidone; Species Specificity

2006
Chronic nicotine interactions with clozapine and risperidone and attentional function in rats.
    Progress in neuro-psychopharmacology & biological psychiatry, 2006, Volume: 30, Issue:2

    Topics: Animals; Antipsychotic Agents; Attention; Behavior, Animal; Clozapine; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Nicotine; Nicotinic Agonists; Rats; Rats, Sprague-Dawley; Reaction Time; Risperidone; Sensory Thresholds; Signal Detection, Psychological

2006
Effects of risperidone on development and expression of nicotine-induced locomotor sensitization in rats.
    Synapse (New York, N.Y.), 2011, Volume: 65, Issue:8

    Topics: Adaptation, Physiological; Animals; Antipsychotic Agents; Male; Motor Activity; Nicotine; Nicotinic Agonists; Rats; Rats, Wistar; Risperidone; Tobacco Use Disorder

2011
Precompetitive consortium approach to validation of the next generation of biomarkers in schizophrenia.
    Biomarkers in medicine, 2014, Volume: 8, Issue:1

    Topics: Antipsychotic Agents; Biomarkers; Humans; Ketamine; Magnetic Resonance Imaging; Nicotine; Risperidone; Schizophrenia

2014
Nicotinic α7 and α4β2 agonists enhance the formation and retrieval of recognition memory: Potential mechanisms for cognitive performance enhancement in neurological and psychiatric disorders.
    Behavioural brain research, 2016, Apr-01, Volume: 302

    Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzamides; Bridged Bicyclo Compounds; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Exploratory Behavior; Female; Indans; Locomotion; Mental Recall; Nicotine; Nicotinic Agonists; Piperidines; Rats; Recognition, Psychology; Retention, Psychology; Risperidone

2016
Methamphetamine-like discriminative stimulus effects of bupropion and its two hydroxy metabolites in male rhesus monkeys.
    Behavioural pharmacology, 2016, Volume: 27, Issue:2-3 Spec I

    Topics: Animals; Antidepressive Agents, Second-Generation; Bupropion; Central Nervous System Stimulants; Conditioning, Operant; Discrimination Learning; Dopamine Antagonists; Dose-Response Relationship, Drug; Macaca mulatta; Male; Methamphetamine; Nicotine; Nicotinic Agonists; Reinforcement, Psychology; Risperidone; Time Factors; Varenicline

2016